ATRA

6.7095.82%
AN

Anhco Nguyen

President, CEO & Director

Dr. Anhco Nguyen, Ph.D., also known as Cokey, has been the President, Chief Executive Officer and Director of Atara Biotherapeutics Inc. since September 09, 2024. He served as Chief Scientific Officer at Atara Biotherapeutics, Inc. since May 2021 until September 09, 2024 and served as its Executive Vice President and Chief Technical Officer since May 2023 until September 09, 2024. Dr. Nguyen comes to Atara from Fate Therapeutics, where, as Vice President, Innovation, Research and Development, he directed strategy for discovery and innovation efforts and spearheaded the corporate collaboration program with ONO Pharma. Prior to that, he was leader of the targeted immunotherapy group on the Oncology R&D team at Pfizer, producing bispecific antibodies for solid tumors and hematological malignancies and bringing them into the clinic. Dr. Nguyen’s bench science experience includes work in tumor metabolism, gene expression and molecular biology. He holds numerous patents for iPSC and immune effector cells and has been published in various peer-reviewed journals. Dr. Nguyen has also been active in successful business development activities, including, while at Janssen, evaluating Legend’s BCMA-directed CAR T program and supporting the Janssen/Legend partnership. Dr. Nguyen served as Vice President of Research and Development at Enumeral Biomedical Holdings, Inc. from July 31, 2014 to August 17, 2016. Dr. Nguyen leads research and development team and is responsible for both proprietary discovery and corporate partnership programs. He participates with Enumeral Biomedical’s business development team in structuring new research collaboration initiatives. He served as Vice President of Research and Development of Enumeral Biomedical Corp. since January 2012. He has significant industry experience in the development of therapeutic antibodies for treatment of cancer and multiple sclerosis having held positions of increasing responsibility, most notably at Forma Therapeutics where he served as a Staff Scientist from June 2009 to January 2012 and Genzyme Corp. where he served as a Staff Scientist from June 2006 to May 2009. He has co-authored numerous articles in the fields of cancer and immunology. He completed postdoctoral training at MIT’s Cancer Center and was the recipient of a Presidential Postdoctoral Fellowship, which he completed at the Novartis Institute for Biomedical Research. Dr. Nguyen received his Ph.D. Immunology from Washington University and his A.B. Biology from Harvard College.

公司职务